Add
NABI to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| NABI > SEC Filings for NABI > Form 8-K on 6-Aug-2009 | All Recent SEC Filings |
6-Aug-2009
Results of Operations and Financial Condition, Other Events, Financial S
On August 6, 2009, Nabi Biopharmaceuticals (the "Company") issued a press release announcing its results of operations for the three and six months ended June 27, 2009. A copy of the press release announcing these results is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
On August 6, 2009, the Company issued a press release announcing it had signed a definitive agreement for the sale of PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline. A copy of the press release is furnished as Exhibit 99.2 to this report.
The information furnished in this Item 8.01 and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Exhibit
number Description
99.1 Earnings Press Release
99.2 PentaStaph Press Release
|
|
|